Cardiovascular effects of sodium glucose cotransporter 2 inhibitors

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) is associated with increased cardiovascular (CV) risk.
• Glucose-lowering agents are increasingly evaluated for their impact on CV outcomes.
• Sodium glucose cotransporter 2 (SGLT2) inhibitors represent a newer class of antidiabetic medications.

Purpose of the Study:

• To review the cardiovascular (CV) outcomes from the EMPAgliflozin Removal of Excess Glucose: Cardiovascular OUTCOME Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial.
• To discuss recently published CV outcomes data for canagliflozin (CANagliflozin CardioVascular Assessment Study - CANVAS Program) and real-world data (CVD-REAL).
• To examine potential mechanisms by which SGLT2 inhibitors may reduce CV risk in T2DM patients, with a focus on EMPA-REG OUTCOME.

Main Methods:

• Review of published data from major cardiovascular outcome trials and real-world studies.
• Focus on the EMPA-REG OUTCOME trial investigating empagliflozin.
• Comparative analysis of SGLT2 inhibitors versus other glucose-lowering drugs.

Main Results:

• The EMPA-REG OUTCOME trial was the first to demonstrate a reduction in CV events with an SGLT2 inhibitor in T2DM patients.
• Recent publications include CV outcomes data for canagliflozin and real-world evidence comparing SGLT2 inhibitors.
• These studies collectively suggest a significant role for SGLT2 inhibitors in mitigating CV risk.

Conclusions:

• SGLT2 inhibitors, exemplified by empagliflozin, offer significant cardiovascular benefits for patients with type 2 diabetes mellitus.
• Further investigation into the mechanisms underlying these CV protective effects is warranted.
• The findings have implications for the management of T2DM, emphasizing CV risk reduction.